Tapan Kadia (@tapkadia) 's Twitter Profile
Tapan Kadia

@tapkadia

Tapan Kadia, MD
- Leukemia Doc at MD Anderson Cancer Center
Leukemia, clinical/translational research. Views, posts and opinions shared are my own.

ID: 701359482

calendar_today17-07-2012 16:36:41

4,4K Tweet

3,3K Takipçi

219 Takip Edilen

MD Anderson Cancer Center (@mdandersonnews) 's Twitter Profile Photo

How do cytopenias, proliferation and JAK2 allele burden impact the outcome of patients with myelofibrosis? Our fellow Dr. Julie Braish shared findings (Abstract 6514) at #ASCO24. Learn more: bit.ly/3V4biEY Julie Braish ASCO #EndCancer

How do cytopenias, proliferation and JAK2 allele burden impact the outcome of patients with myelofibrosis? Our fellow Dr. Julie Braish shared findings (Abstract 6514) at #ASCO24. 

Learn more: bit.ly/3V4biEY <a href="/BraishJulie/">Julie Braish</a> <a href="/ASCO/">ASCO</a> #EndCancer
MD Anderson Cancer Center (@mdandersonnews) 's Twitter Profile Photo

A triplet combination of venetoclax, cladribine and low-dose cytarabine offers favorable outcomes in older patients with acute myeloid leukemia, according to a study led by our Dr. Tapan Kadia. Read about this and more advances from MD Anderson: bit.ly/3x3J2ua Tapan Kadia

Naveen Pemmaraju, MD (@doctorpemm) 's Twitter Profile Photo

👉👉👉Honored to present #EHA24 #EHA2024 today 👉#TRANSFORM-1 results randomized ph3 clinical trial. RUXO+#NAVITOCLAX frontline vs RUXO+placebo n=252, Med f/u 20.3 mo. SVR35w24= 63.2% NaV+RuXo vs 31.5% in RUXO+PLCBO ➡️Primary Endpoint met| #MPNSM European Hematology Association Claire Harrison

👉👉👉Honored to present #EHA24 #EHA2024 today 👉#TRANSFORM-1 results randomized ph3 clinical trial.  RUXO+#NAVITOCLAX  frontline vs RUXO+placebo n=252, Med f/u 20.3 mo.  SVR35w24= 63.2% NaV+RuXo vs 31.5% in RUXO+PLCBO ➡️Primary Endpoint met| #MPNSM <a href="/EHA_Hematology/">European Hematology Association</a> <a href="/harrisoncn1/">Claire Harrison</a>
AML Hub (@aml_hub) 's Twitter Profile Photo

CONGRESS | #EHA2024 | Poster Tapan Kadia Tapan Kadia, MD Anderson Cancer Center, presents findings of a phase II study evaluating cladribine, idarubicin, and higher dose cytarabine (CLIA) in pts with R/R AML (N=98). ▪️ After 1-2 courses to best response, ORR (CR/CRi) was 42% of whom 61% pts

CONGRESS | #EHA2024 | Poster
Tapan Kadia <a href="/TapKadia/">Tapan Kadia</a>, <a href="/MDAndersonNews/">MD Anderson Cancer Center</a>, presents findings of a phase II study evaluating cladribine, idarubicin, and higher dose cytarabine (CLIA) in pts with R/R AML (N=98).
▪️ After 1-2 courses to best response, ORR (CR/CRi) was 42% of whom 61% pts
Nitin Jain (@nitinjainmd) 's Twitter Profile Photo

Dr Emmanuel Almanza Emmanuel Almanza-Huante is most wonderful human being you will ever meet Completing Leukemia fellowship today A wonderful presence in the clinic for last 2 years! (With Sarah, RN and Victoria, PA) All the BEST #dedication #determination #respect #bestwishes

Dr Emmanuel Almanza <a href="/AlmanzaLeukMD/">Emmanuel Almanza-Huante</a> is most wonderful human being you will ever meet
Completing Leukemia fellowship today
A wonderful presence in the clinic for last 2 years! (With Sarah, RN and Victoria, PA) 
All the BEST
#dedication #determination #respect 
#bestwishes
Nitin Jain (@nitinjainmd) 's Twitter Profile Photo

👉👉👉Delighted to share review article on #CLL (with my colleagues Drs Bill Wierda and Susan O’Brien) published in the Journal Lancet today!! The Lancet Bill Wierda, MD, PhD MD Anderson Cancer Center Hagop Kantarjian,MD Chronic lymphocytic leukaemia - The Lancet thelancet.com/journals/lance…

👉👉👉Delighted to share review article on #CLL (with my colleagues Drs Bill Wierda and Susan O’Brien) published in the Journal Lancet today!! <a href="/TheLancet/">The Lancet</a> 
<a href="/wwierda/">Bill Wierda, MD, PhD</a> <a href="/MDAndersonNews/">MD Anderson Cancer Center</a> <a href="/DrHKantarjian/">Hagop Kantarjian,MD</a> 

Chronic lymphocytic leukaemia - The Lancet thelancet.com/journals/lance…
Brittany Knick Ragon, MD (@bkragonmd) 's Twitter Profile Photo

An honor to join this group of brilliant (and kind) humans doing extraordinary work DAVA Oncology #DAVAHeme AK Eisfeld Tapan Kadia Firas El Chaer, MD, MSHCM - thanks to our moderator for the emphatic supportive head nods even when we went over time!!

Jayastu Senapati (@jayastumd) 's Twitter Profile Photo

👉🏽 Check out our recent paper on the outcomes of N/D patients with AML having WBC >100x10e9 at presentation ✅63% had FLT3 mut ✅8 week mortality of 13%: all in pts >65 years ✅Age>65, LDH>2000, high lactates, adverse CTG prognostic for OS Fadi Haddad, MD Hagop Kantarjian,MD Tapan Kadia

ACS Journal Cancer (@journalcancer) 's Twitter Profile Photo

Read our Oct 1 issue! 📗 acsjournals.onlinelibrary.wiley.com/toc/10970142/2… ✅ Targeted lung therapy advs by Makarem & Jänne of Dana-Farber ✅ Out-of-pocket costs after #ProstateCancer screening by Anca Tilea et al ✅ Jayastu Senapati & Tapan Kadia et al on post SCT outcomes in older pats w/ AML OncoAlert

Fadi Haddad, MD (@fadihaddad_md) 's Twitter Profile Photo

🔥 So excited for Guillermo Montalban-Bravo & Shilpa Paul for becoming parents 👨‍👩‍👦 #leukemia work will need to be paused 😅 He will join the baby-boy leukemia gang 😎 #babyshower #papa #mama

🔥 So excited for <a href="/GMontalbanBravo/">Guillermo Montalban-Bravo</a> &amp; <a href="/SPaul_PharmD/">Shilpa Paul</a> for becoming parents 👨‍👩‍👦
#leukemia work will need to be paused 😅
He will join the baby-boy leukemia gang 😎

#babyshower #papa #mama